EDGE INVESTOR ALERT

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Edge Therapeutics, Inc. Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Edge Therapeutics, Inc. (“Edge Therapeutics” or the “Company”) (NASDAQ: EDGE) securities between December 29, 2017 and March 27, 2018, inclusive (the “Class Period”). Edge Therapeutics investors have until June 22, 2018 to file a lead plaintiff motion.

Investors that suffered losses on their Edge Therapeutics investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [e-mail].

The complaint filed in this class action alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company’s lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study; and, (2) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Edge’s business, operations, and prospects, were materially false and misleading at all relevant times.

On March 28, 2018, Edge Therapeutics disclosed, “that a pre-specified interim analysis on data from the Day 90 visit of the first 210 subjects randomized and treated in the Phase 3 NEWTON 2 study of EG-1962 demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the study’s primary endpoint, if the study is fully enrolled.” As a result, the Data Monitoring Committee “recommended that the study be stopped based on its conclusion that the study has a low probability of meeting its primary endpoint.” Based on the DMC recommendation, Edge Therapeutics stated that it has decided to discontinue the Phase 3 NEWTON 2 study.

On this news, shares of Edge Therapeutics fell $14.28 per share, or nearly 92%, to close at $1.31 per share on March 28, 2018, thereby injuring investors.

If you purchased shares of Edge Therapeutics during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at [phone], toll-free at [phone], or by email to [e-mail], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180614006241/en/